

PROGRAM OF EVENTS

SOHO 2019

WEDNESDAY, SEPTEMBER 11, 2019

TIME	TOPIC/SESSION	SPEAKER	AFFILIATION/ROOM
------	---------------	---------	------------------

INDEPENDENT SATELLITE SYMPOSIUM I

6:15 AM	Independent Satellite Symposium - Waldenström Macroglobulinemia: Expert Insights on Current and Emerging Treatment Options		
---------	--	--	--

BREAKFAST WITH THE EXPERT I

6:45 AM	Breakfast with the Expert: Optimizing Care for the Older Adolescent and Young Adult: Perspectives from Two Sides of the Ocean	Wendy Stock, MD	The University of Chicago, Chicago, Illinois, USA
		Nicolas Boissel, MD, PhD	Hôpital Saint-Louis , Paris, France

7:45 AM **BREAK**

MEET-THE-PROFESSOR SESSIONS

8:00 AM MTP Session I: CML

Session Chair: Delphine Rea

New Kinase Inhibitors for CML	Michael J. Mauro, MD, PhD	Memorial Sloan-Kettering Cancer Center, New York, New York, USA
New T Cell Targets in CML	Jerald P. Radich, MD	Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Novel Approaches to Blast Crisis CML	Elias Jabbour, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

8:00 AM MTP Session II: ALL

Session Chair: Ching-Hon Pui

Targeted Cellular Therapy for ALL	Partow Kebriaei, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Childhood ALL: How To Cure The Very High Risk?	Ching-Hon Pui, MD	St. Jude Children's Research Hospital, Memphis, Tennessee, USA
The Future of ALL Treatment	Nicolas Boissel, MD, PhD	Hôpital Saint-Louis , Paris, France

8:00 AM MTP Session III: AML

Session Chair: Farhad Ravandi

Harnessing the Immune System for Treating AML	Farhad Ravandi, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Manipulating the Microenvironment in AML	Daniel J. DeAngelo, MD, PhD	Dana-Farber Cancer Institute, Boston, Massachusetts, USA
IDH inhibitors in AML	Courtney D. DiNardo, MD, MSCE	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

8:00 AM MTP Session IV: MPN

Session Chair: Elliott Winton

Identification for and Management of Patient with PV and MF with Ruxolitinib	Srdan Verstovsek, MD, PhD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Combination Approaches With Ruxolitinib in MF	Laura C. Michaelis, MD	Medical College of Wisconsin, Milwaukee, Wisconsin, USA
MF Management After Ruxolitinib Failure	Elliott F. Winton, MD	Emory University Hospital, Atlanta, Georgia, USA

PROGRAM OF EVENTS

SOHO 2019

8:00 AM **MTP Session V: NHL**

Session Chair: Kieron Dunleavy

Double Hit Lymphoma

Kieron M. Dunleavy, MD

George Washington University Cancer Center,
Washington, DC, USA

Is There A Role for BCL2 Inhibitors in DLBCL

Andrew D. Zelenetz, MD, PhD

Memorial Sloan-Kettering Cancer Center, New
York, New York, USA

How to Treat Elderly Patients with CHL

Alison J. Moskowitz, MD

Memorial Sloan-Kettering Cancer Center, New
York, New York, USA

8:00 AM **MTP Session VI: MDS**

Session Chair: Lucy Godley

Pre-MDS: CHIP, CCUS, ICUS

Lucy A. Godley, MD, PhD

The University of Chicago, Chicago, Illinois, USA

Management of Lower Risk MDS

Rami Komrokji, MD

H. Lee Moffitt Cancer Center and Research
Institute, Tampa, Florida, USA

Management of Higher Risk MDS

Valeria Santini, MD

University of Florence, Florence, Italy

8:00 AM **MTP Session VII: CLL**

Session Chair: Neil Kay

Genetics of CLL

Richard Rosenquist Brandell, MD,
PhD

Karolinska Institutet, Stockholm, Sweden

Clonal Evolution in CLL

Davide Rossi, MD, PhD

Institute of Oncology Research, Bellinzona,
Switzerland

Mechanisms of Resistance in CLL

Paolo Ghia, MD, PhD

Università Vita-Salute San Raffaele, Milano, Italy

8:00 AM **MTP Session VIII: MM**

Session Chair: Sagar Lonial

What Is The Optimal Induction Therapy for MM

Amrita Y. Krishnan, MD, FACP

City of Hope National Medical Center, Duarte,
California, USA

Real World Treatment of Patients with Relapsed/
Refractory Disease

Meletios Dimopoulos, MD

University of Athens, Athens, Greece

8:00 AM **MTP Session IX: Advanced Oncology Nurse**

Session Chair:

TBD

TBD

8:00 AM **MTP Session X: Cellular Therapy**

Session Chair:

Setting Up a CAR T Program Ins and Outs

Sergio Giralt, MD

Memorial Sloan-Kettering Cancer Center, New
York, New York, USA

9:15 AM **BREAK**

PROGRAM OF EVENTS

SOHO 2019

SESSION I: CHRONIC MYELOID LEUKEMIA

Session Chairs: Timothy Hughes and Michael Deininger

9:30 AM	Welcome and Opening Remarks	Ching-Hon Pui, MD	President, Society of Hematologic Oncology
9:40 AM	CML: State of the Art Update	Jorge Cortés, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
9:55 AM	Therapeutic Innovations in CML	Michael Deininger, MD, PhD	Huntsman Cancer Hospital, The University of Utah, Salt Lake City, Utah, USA
10:10 AM	TFR: Impact of Depth and Duration of Response	Delphine Rea, MD, PhD	Hôpital Saint Louis, Paris, France
10:25 AM	CASE PRESENTATION: Treatment Choices: Impact of Comorbidities	Timothy P. Hughes, MD, FRACP, FRCPA	South Australian Health and Medical Research Institute, Adelaide, Australia
10:40 AM	CASE PRESENTATION: Allograft Versus Third-Line Therapy	Jerald P. Radich, MD	Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
10:55 AM	Oral Abstract		
11:05 AM	Oral Abstract		

SESSION II: MYELOPROLIFERATIVE NEOPLASMS

Session Chairs: Robert Kralovics and David Snyder

11:15 AM	MPN State of the Art Update: Stem Cell Niche in MPN	Robert Kralovics, PhD	Medical University of Vienna, Vienna, Austria
11:30 AM	Primer on CNL and aCML Diagnosis and Therapy	Uma Borate, MD, MS	Oregon Health & Science University, Portland, Oregon, USA
11:45 AM	Identifying and Treating "Progression" in MF	Prithviraj Bose, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
12:00 PM	Evolution of Transplant Approaches in MPN	David S. Snyder, MD, FACP	City of Hope National Medical Center, Durate, California, USA
12:15 PM	Immunogenicity of MPN: A New Way Forward?	Robert Kralovics, PhD	Medical University of Vienna, Vienna, Austria
12:30 PM	Oral Abstract		
12:40 PM	Oral Abstract		

INDUSTRY EXPERT SESSION I

12:50 PM Industry Expert Lunch Session

PLENARY SESSION I

Session Chair: Hagop Kantarjian

2:20 PM	Impact of Molecular Signature on Prognostication in MPN <i>Recipient of the SOHO 2019 Distinguished Lecturer Award</i>	Ayalew Tefferi, MD	Mayo Clinic Rochester, Rochester, Minnesota, USA
---------	---	--------------------	--

SESSION III: MULTIPLE MYELOMA

Session Chairs: Sagar Lonial and Robert Orlowski

2:40 PM	Non-Antibody Based Immune Therapy	Nina Shah, MD	University of California San Francisco, San Francisco, California, USA
2:55 PM	Role of HDT in MM: 2019	Maria-Victoria Mateos, MD, PhD	University Hospital of Salamanca, Spain
3:10 PM	Bone Disease and Management	Jens Hillengass, MD	Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA
3:25 PM	BREAK		

PROGRAM OF EVENTS

SOHO 2019

3:55 PM	DEBATE: Can MRD Be Used for Treatment Decisions? Yes	Jeffrey L. Wolf, MD	University of California San Francisco, San Francisco, California, USA
4:10 PM	DEBATE: Can MRD Be Used for Treatment Decisions? No	Thomas G. Martin, MD	University of California San Francisco, San Francisco, California, USA
4:25 PM	Amyloid Therapy and Targets	Suzanne Lentzsch, MD, PhD	Columbia University and at New York Presbyterian Hospital, New York, USA
4:40 PM	Induction Therapy for Newly Diagnosed MM: What to Use in the Era of Monoclonal Antibodies	Ajay K. Nooka, MD, MPH, FACP	Winship Cancer Institute of Emory University, Atlanta, Georgia, USA
4:55 PM	Oral Abstract		
5:05 PM	Oral Abstract		
5:15 PM	ADJOURN		

POSTER SESSION & WELCOME RECEPTION

5:15 PM **POSTER SESSION, WELCOME RECEPTION AND AWARDS**

THURSDAY, SEPTEMBER 12, 2019

TIME TOPIC/SESSION SPEAKER AFFILIATION/ROOM

INDEPENDENT SATELLITE SYMPOSIUM II

6:15 AM Independent Satellite Symposium

BREAKFAST WITH THE EXPERT II

6:45 AM Breakfast with the Expert: BCL-2 Inhibition in AML Marina Konopleva, MD, PhD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

7:45 AM **BREAK**

SESSION IV: ACUTE LYMPHOBLASTIC LEUKEMIA

Session Chairs: Wendy Stock and Dieter Hoelzer

8:00 AM	CAR-T therapy for ALL: Moving Beyond Single Agent Targeting	Nirali N. Shah, M.D., MHSc	Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
8:15 AM	DEBATE: Is Transplant Still Necessary in the Era of Targeted Cellular Therapy for ALL? PRO	Partow Kebriaei, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
8:30 AM	DEBATE: Is Transplant Still Necessary in the Era of Targeted Cellular Therapy for ALL? CON	Michael A. Pulsipher, MD	Children's Hospital Los Angeles, University of Southern California, Los Angeles, California, USA
8:45 AM	Combining Genotype Profiling with MRD for More Accurate Prognostication in ALL	Jack Bartram, MD	Great Ormond Street Hospital for Children, NHS Foundation Trust, London, United Kingdom
9:00 AM	Ph+ ALL: How Can We Optimize Treatment for All Patients?	Sabina Chiaretti, MD, PhD	La Sapienza University, Rome, Italy
9:15 AM	Progress in the Management of Adult ALL	Dieter Hoelzer, MD, PhD	Onkologikum, Frankfurt am Museumsufer, Germany
9:30 AM	Novel Therapies in Older Patients with Ph- B-Cell ALL	Elias Jabbour, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
9:45 AM	The Challenge of Improving Outcomes for T-ALL: Approach to ETP ALL and Relapsed Disease	Bijal D. Shah, MD	H. Lee Moffitt Cancer Center, Tampa, Florida, USA
10:00 AM	Oral Abstract		
10:10 AM	Oral Abstract		
10:20 AM	BREAK		

PROGRAM OF EVENTS

SOHO 2019

SESSION V: MYELODYSPLASTIC SYNDROMES

Session Chairs: Guillermo Garcia-Manero and Amit Verma

10:50 AM	MDS State of the Art Update: Emerging Targeted Therapeutics for MDS	Guillermo Garcia-Manero, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
11:05 AM	Progress in Targeting the TGFb Pathway	Amit Verma, MD	Albert Einstein College of Medicine, Bronx, New York, USA
11:20 AM	CASE PRESENTATION: Managing TP53-Mutant MDS	David Sallman, MD	H. Lee Moffitt Cancer Center, Tampa, Florida, USA
11:35 AM	CASE PRESENTATION: Iron Chelation Therapy – The Final Answer	Emanuele Angelucci, MD	Ospedale Policlinico San Martino, Genova, Italy
11:50 AM	Novel Chromatin Modulation Strategies In MDS	Michael R. Savona, MD	Vanderbilt University Medical Center, Nashville, Tennessee, USA
12:05 PM	Preventing Relapse Following Allogenic Stem Cell Transplant	Uwe Platzbecker, MD, PhD	University Hospital “Carl Gustav Carus”, Dresden, King’s College London, Dresden, Germany
12:20 PM	Oral Abstract		
12:30 PM	Oral Abstract		

INDUSTRY EXPERT SESSION II

12:40 PM **Industry Expert Lunch Session**

PLENARY SESSION II

Session Chair: Ching-Hon Pui, MD

2:10 PM	Can the Newest Insights In the Molecular Pathogenesis of B-ALL Lead to New Therapeutic	Charles G. Mullighan, MBBS (Hons), MSc, MD	St. Jude Children's Research Hospital, Memphis, Tennessee, USA
---------	--	--	--

SESSION VI: ACUTE MYELOID LEUKEMIA

Session Chairs: Richard Stone and Eunice Wang

2:30 PM	AML State of the Art Update	Selina M. Luger, MD	University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, USA
2:45 PM	CART Cells in AML	Stephen J. Forman, MD	City of Hope National Medical Center, Duarte, California, USA
3:00 PM	Novel Strategies in High Risk AML	John S. Welch, MD, PhD	Washington University School of Medicine, St. Louis, Missouri, USA
3:15 PM	ADC, DARTs and Bites in AML	John DiPersio, MD, PhD	Washington University School of Medicine, St. Louis, Missouri, USA
3:30 PM	DEBATE: Should All Older AML Patients and Younger Patients with Adverse Biology Routinely Receive HMA/Ventoclax Instead of 3+7/Standard Induction? PRO	Daniel Pollyea, MD, MS	University of Colorado, Denver, Colorado, USA
3:45 PM	DEBATE: Should All Older AML Patients and Younger Patients with Adverse Biology Routinely Receive HMA/Ventoclax Instead of 3+7/Standard Induction? CON	Jeffrey E. Lancet, MD	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
4:00 PM	BREAK		
4:30 PM	Use of MRD in AML	Pau Montesinos, MD	University Hospital La Fe, Valencia, Spain
4:45 PM	Use of FLT3 Inhibitors in AML	Catherine Smith, MD	University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA
5:00 PM	Use of Gemtuzumab in AML	Roland B. Walter, MD, PhD	Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington, USA

PROGRAM OF EVENTS

SOHO 2019

5:15 PM Oral Abstract

5:25 PM Oral Abstract

5:35 PM Oral Abstract

INDUSTRY EXPERT SESSION III

5:45 PM Industry Expert Dinner Session

FRIDAY, SEPTEMBER 13, 2019

TIME	TOPIC/SESSION	SPEAKER	AFFILIATION/ROOM
------	---------------	---------	------------------

INDEPENDENT SATELLITE SYMPOSIUM III

6:15 AM Independent Satellite Symposium

BREAKFAST WITH THE EXPERT III

6:45 AM	Breakfast with the Expert: Marginal Zone Lymphoma	Emanuele Zucca, MD	Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
---------	---	--------------------	---

7:45 AM BREAK

SESSION VII: HODGKIN LYMPHOMA

Session Chairs: Pier Luigi Zinzani and Stephen Ansell

8:00 AM	Early Stage HL	Andrew M. Evens, DO, MSc, FACP	Rutgers Cancer Institute, New Brunswick, New Jersey, USA
---------	----------------	--------------------------------	--

8:15 AM	Advanced Stage HL	Pier Luigi Zinzani, MD	University of Bologna, Bologna, Italy
---------	-------------------	------------------------	---------------------------------------

8:30 AM Oral Abstract

SESSION VIII: INDOLENT B-CELL LYMPHOMA

Session Chairs: Nathan Fowler and Robert Marcus

8:40 AM	Chemo Free vs Chemotherapy Based Front Line Therapy	Nathan H. Fowler, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
---------	---	----------------------	--

8:55 AM	CD20-Based Bi-Specific Antibody Therapy	Martin Hutchings, MD, PhD	The Finsen Center, National Hospital Copenhagen University Hospital, Copenhagen, Denmark
---------	---	---------------------------	--

9:10 AM	PI3K Inhibitors	Andrew D. Zelenetz, MD, PhD	Memorial Sloan-Kettering Cancer Center, New York, New York, USA
---------	-----------------	-----------------------------	---

9:25 AM	Optimal Use of Bendamustine in FL	Mathias J. Rummel, MD, PhD	Justus-Liebig University-Hospital, Giessen, Germany
---------	-----------------------------------	----------------------------	---

9:40 AM	Role of Radiation Therapy in The Management of Gastric MALT Lymphoma	Joachim Yahalom, MD, FACR	Memorial Sloan-Kettering Cancer Center, New York, New York, USA
---------	--	---------------------------	---

9:55 AM Oral Abstract

10:05 AM BREAK

SESSION IX: AGGRESSIVE B-CELL LYMPHOMA

Session Chair: Anas Younes and Laurie Sehn

10:35 AM	Is There A Role for RCHOP + Drug X Strategy	Anas Younes, MD	Memorial Sloan-Kettering Cancer Center, New York, New York, USA
----------	---	-----------------	---

10:50 AM	CAR T-Cells	David G. Maloney, MD, PhD	Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
----------	-------------	---------------------------	--

11:05 AM	Antibody Drug Conjugates	Laurie Sehn, MD	The University of British Columbia, Vancouver, Canada
----------	--------------------------	-----------------	---

PROGRAM OF EVENTS

SOHO 2019

11:20 AM CNS Toxicity of CAR T-Cell Therapy Bianca D. Santomaso, MD, PhD Memorial Sloan-Kettering Cancer Center, New York, New York, USA

11:35 AM Oral Abstract

11:45 AM Oral Abstract

11:55 AM Oral Abstract

INDUSTRY EXPERT SESSION IV

12:05 PM Industry Expert Lunch Session

PLENARY SESSION III

Session Chair: Sergio Giralt

1:35 PM Future of Cellular Therapy Elizabeth J. Shpall, MD MD Anderson Cancer Center, Houston, Texas, USA

SESSION X: T-CELL LYMPHOMA

Session Chairs: Julie Vose and Philippe Gaulard

1:55 PM New Frontline Regimens Julie Vose, MD, MBA University of Nebraska Medical Center, Omaha, Nebraska

2:10 PM New Therapy for Relapsed T-Cell Lymphoma Owen A. O'Connor, MD, PhD. Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, USA

2:25 PM New Insights into the Molecular Pathogenesis of T-Cell Lymphoma Philippe Gaulard, MD Hôpital Henri Mondor, Paris, France

2:40 PM Oral Abstract

2:50 PM BREAK

SESSION XI: MANTLE CELL LYMPHOMA

Session Chair: Simon Rule and Andrew Zelenetz

3:20 PM What Is the Standard Front Line Therapy for MCL? Simon Rule, MD University of Plymouth, Derriford Hospital, Plymouth, United Kingdom

3:35 PM Novel Salvage Therapy Andre Goy, MD, MS Hackensack University Medical Center, Hackensack, New Jersey, USA

3:50 PM Who Is a Candidate for Watch and Wait Therapy Anita Kumar, MD Memorial Sloan-Kettering Cancer Center, New York, New York, USA

4:05 PM Oral Abstract

SESSION XII: CELLULAR THERAPY

Session Chairs: Sergio Giralt and Renier Brentjens

4:15 PM Off the Shelf CAR T Cells Ewelina Morawa, MD CRISPR Therapeutics, Cambridge, Mass, USA

4:30 PM NK CAR Katy Rezvani, MD, PhD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

4:45 PM Not All About CARs-Future of CTL's Catherine Bollard, MD, MBChB National Childrens Hospital, Washington, DC, USA

5:00 PM Conduct of Adoptive T Cell Therapies Frederick Locke, MD H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, USA

5:15 PM Oral Abstract

5:25 PM ADJOURN

PROGRAM OF EVENTS

SOHO 2019

INDUSTRY EXPERT SESSION V

5:30 PM Industry Expert Session: Hors d'Oeuvres and Drinks

INDUSTRY EXPERT SESSION VI

6:30 PM Industry Expert Session: Dinner

SATURDAY, SEPTEMBER 14, 2019

TIME	TOPIC/SESSION	SPEAKER	AFFILIATION/ROOM
------	---------------	---------	------------------

INDEPENDENT SATELLITE SYMPOSIUM IV

6:15 AM Independent Satellite Symposium

BREAKFAST WITH THE EXPERT IV

6:45 AM	Breakfast With the Expert: Sequential vs Combination Therapy in CLL	John C. Byrd, MD	Ohio State University, James Comprehensive Cancer Center, Columbus, Ohio, USA
---------	---	------------------	---

7:45 AM **BREAK**

SESSION XIII: CHRONIC LYMPHOCYTIC LEUKEMIA

Session Chairs: Susan O'Brien and Emili Montserrat

8:00 AM	CLL: State of the Art Update	Jennifer R. Brown, MD, PhD	Dana-Farber Cancer Institute, Boston, Massachusetts, USA
8:15 AM	Shifting SOC for Frontline Therapy of CLL	Nitin Jain, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
8:30 AM	Next Generation Small Molecules	Jennifer A. Woyach, MD	Ohio State University, James Comprehensive Cancer Center, Columbus, Ohio, USA
8:45 AM	CASE PRESENTATION:	Alessandra Ferrajoli, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
9:00 AM	CAR-T Cell Therapy in CLL	Tanya Siddiqi, MD	City of Hope National Medical Center, Duarte, California, USA
9:15 AM	How Have Prognostic Factors Changed with Novel Therapies	Adrian U. Wiestner, MD, PhD	National Cancer Institute, Bethesda, Maryland, USA
9:30 AM	Oral Abstract		
9:40 AM	Oral Abstract		
9:50 AM	BREAK		

SESSION XIV: NEXT QUESTIONS

Session Chairs: Hagop Kantarjian and TBD

10:20 AM	Next Questions: Acute Lymphoblastic Leukemia	Hagop Kantarjian, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
10:30 AM	Next Questions: Acute Myeloid Leukemia	Eunice S. Wang, MD	Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA
10:40 AM	Next Questions: Cellular Therapy: Point of Care CAR T Cell	Boro Dropulic, PhD	Lentigen Technology, Inc., Miltenyi Corporation, Gaithersburg, Maryland, USA
10:50 AM	Next Questions: Chronic Lymphocytic Leukemia	William Wierda, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
11:00 AM	Next Questions: Chronic Myeloid Leukemia	Moshe Talpaz, MD	University of Michigan, Ann Arbor, Michigan, USA
11:10 AM	Next Questions: Aggressive B-Cell Lymphoma	Anas Younes, MD	Memorial Sloan-Kettering Cancer Center, New York, New York, USA
11:20 AM	Next Questions: Indolent B-Cell Lymphoma	Robert Marcus, MA, FRCP, FRCPath	Leaders in Oncology Care, London, United Kingdom
11:30 AM	Next Questions: T-Cell Lymphoma	Owen A. O'Connor, MD, PhD	Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, USA

PROGRAM OF EVENTS

SOHO 2019

11:40 AM	Next Questions: Mantle Cell Lymphoma	Simon Rule, MD	University of Plymouth, Derriford Hospital, Plymouth, United Kingdom
11:50 AM	Next Questions: Hodgkin Lymphoma	Stephen M. Ansell, MD, PhD	Mayo Clinic Rochester, Minnesota, USA
12:00 PM	Next Questions: Myelodysplastic Syndromes	Guillermo Garcia-Manero, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
12:10 PM	Next Questions: Myeloproliferative Neoplasms	Srdan Verstovsek, MD, PhD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
12:20 PM	POSTER AWARDS, DRAWING AND CLOSING REMARKS		
12:35 PM	ADJOURN		